Impact of Brachytherapy Fractionation on Treatment Outcomes in Carcinoma Cervix: A Three-Year Response Evaluation from a Single-Center Retrospective Study
Journal of Ahsania Mission of Cancer & General Hospital · 01.07.2026 · 69
DOI: 10.65292/jamcgh.2026.v2e2.04 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ahsania Mission of Cancer & General Hospital, online erschienen am 01.07.2026. Verfasst von (Lt Col) Shaila Sharmin und 4 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
Background
Carcinoma cervix remains a major cause of cancer-related morbidity and mortality, particularly in developing countries. For patients with locally advanced disease, concurrent chemoradiotherapy followed by intracavitary brachytherapy is the standard therapeutic approach. This study aimed to compare the treatment response, clinical outcomes, and treatment related toxicities of two brachytherapy fractionation schedules over a three-year follow-up period.
Methods
This retrospective observational study was conducted in Department of Radiation Oncology, Combined Military Hospital, Dhaka, from January 2020 and December 2023. The study w included 82 histologically confirmed cervical carcinoma patients. All patients received EBRT with concurrent chemotherapy followed by intracavitary brachytherapy using either 6 Gy × 4 fractions (Group A) or 7 Gy × 3 fractions (Group B). Clinical outcomes, survival, and treatment-related toxicities were evaluated over three years.
Results
The mean age of patients was 52.4 ± 9.8 years with squamous cell carcinoma being the predominant histological subtype (87.8%). At six months, complete response was observed in 84.1% of Group A and 80.5% of Group B patients. The two-year local control rates were 78.0% and 74.3%, respectively. Disease-free survival at two years was slightly higher in Group A (72.7%) compared to Group B (68.2%), however the difference was not statistically significant (p > 0.05). Grade II or higher rectal and bladder toxicities occur more frequently in Group B. Both treatment groups showed satisfactory treatment compliance.
Conclusion
Both brachytherapy fractionation schedules achieved favorable treatment response and local control in carcinoma cervix patients. The 6 Gy × 4 fraction schedule showed marginally better disease control with fewer late toxicities. However larger prospective multicenter studies are recommended to establish optimal brachytherapy fractionation protocols for cervical cancer.
Zitieren
APA
Sharmin, L. C. S., Rokonuzzaman, C. S., Sultana, L. C. N., Afroz, M. S., & Islam, M. K. (2026). Impact of Brachytherapy Fractionation on Treatment Outcomes in Carcinoma Cervix: A Three-Year Response Evaluation from a Single-Center Retrospective Study. Journal of Ahsania Mission of Cancer & General Hospital, 69. https://doi.org/10.65292/jamcgh.2026.v2e2.04
Vancouver
Sharmin LCS, Rokonuzzaman CS, Sultana LCN, Afroz MS, Islam MK. Impact of Brachytherapy Fractionation on Treatment Outcomes in Carcinoma Cervix: A Three-Year Response Evaluation from a Single-Center Retrospective Study. Journal of Ahsania Mission of Cancer & General Hospital. 2026:69. doi:10.65292/jamcgh.2026.v2e2.04
BibTeX
@article{Sharmin2026,
author = {Sharmin, (Lt Col) Shaila and Rokonuzzaman, (Col) SM and Sultana, (Lt Col) Nazat and Afroz, (Maj) Sadia and Islam, Maj Khairul},
title = {Impact of Brachytherapy Fractionation on Treatment Outcomes in Carcinoma Cervix: A Three-Year Response Evaluation from a Single-Center Retrospective Study},
journal = {Journal of Ahsania Mission of Cancer & General Hospital},
year = {2026},
pages = {69},
doi = {10.65292/jamcgh.2026.v2e2.04}
}
EUVIMED